Abstract:What is known and objectiveThere are numerous studies on population pharmacokinetics of vancomycin in adult patients. However, there is no such research for Chinese adult patients. This study was conducted to evaluate the predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients and to identify some models appropriate for our population.MethodsA literature search was conducted in PubMed to obtain the population pharmacokinetic models of vancomycin published between December 2010 and September 2012. The models were assessed using concentration data collected from Chinese patients for external validation. Models with relatively poor predictability were excluded from further analysis. The performance of the remaining models was evaluated in patients with different levels of creatinine clearance, age, body weight and sex by Bayesian method. This method was also used to compare the predictive performance based on peak concentration and trough concentration and the predictability based on different number of observed concentrations.ResultsOne hundred and sixty-five blood concentrations from 72 Chinese adult patients were collected retrospectively to serve as the test data set. The evaluated models included all those reported in the seven publications reviewed by Marsot etal. and three other studies published after December 2010. Three models with poor performance on external validation were excluded from the next Bayesian analysis. The distribution of covariates in the model building data set had an important effect on prediction. The predictability based on peak/trough concentration was similar among the evaluated models, and no significant difference was found using our data set except for Roberts' model. As expected, an increased number of samples improved the performance of the Bayesian prediction.What is new and conclusionWith our data set, the performance of the evaluated models varied. The characteristics of the patient population and distribution of covariates should be given more consideration when choosing a model to predict blood concentrations. The model developed by Purwonugroho etal. using a data set from patients similar to ours is appropriate for Bayesian dose predictions for vancomycin concentrations in our population of Chinese adult patients.

Predictive Performance of Reported Population Pharmacokinetic Models of Vancomycin in Chinese Adult Patients

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

Population Pharmacokinetics of Vancomycin and Prediction of Pharmacodynamics in the Chinese People

Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients

External validation of vancomycin population pharmacokinetic models in ten cohorts of infected Chinese patients

Initial Dosage Regimens Of Vancomycin For Chinese Adult Patients Based On Population Pharmacokinetic Analysis

Evaluation of the population pharmacokinetic models of vancomycin in geriatric patients

Population Pharmacokinetics Of Vancomycin In Chinese Pediatric Patients

Population Pharmacokinetics Model of Vancomycin in Chinese Adult Patients

Population Pharmacokinetics Modeling of Vancomycin Among Chinese Infants With Normal and Augmented Renal Function

External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers

Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients

Application of machine learning combined with population pharmacokinetics to improve individual prediction of vancomycin clearance in simulated adult patients

Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections.

Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance

[Population Pharmacokinetics of Vancomycin from Severe in Patients with Lower Respiratory Tract Infection].

An Ensemble Model for Prediction of Vancomycin Trough Concentrations in Pediatric Patients

Comparison of the predictive accuracy of the physiologically based pharmacokinetic (PBPK) model and population pharmacokinetic (PPK) model of vancomycin in Japanese patients with MRSA infection

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Vancomycin population pharmacokinetic models: Uncovering pharmacodynamic divergence amid clinicobiological resemblance

Vancomycin in Neonatal Sepsis: Predictive Performance of a Chinese Neonatal Population Pharmacokinetic Model and Clinical Efficacy Evaluation